Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.

Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y, Wagar EA, Wu X. Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. Clin Chem. 2014 Jan; 60(1):222-32.

View in: PubMed

subject areas

Antineoplastic Agents
Female
Fibroblast Growth Factors
Genetic Variation
Genotype
Humans
Middle Aged
Ovarian Neoplasms
Reference Standards
Risk Factors
Signal Transduction
Treatment Outcome

authors with profiles

Dong Liang

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support